SlideShare une entreprise Scribd logo
1  sur  25
PRESENTED BYPRESENTED BY:-:-
Prafulla C TiwariPrafulla C Tiwari
M.Pharm (2M.Pharm (2ndnd
sem)sem)
PharmacologyPharmacology
UNDER THE
GUIDANCE OF:-
MR. RUPESH GAUTAM
(Lecturer)
Department Of
Pharmacology
 The immune system evolved to discriminate self
from nonself.
 Multicellular organism shows immune response by
destroying infectious invaders (microbes) while
leaving normal cells intact.
 Immunity system shows two types of responses
that are-
1.Innate immunity
2.Adaptive immunity
1.Innate, or natural immunity-It is primitive, does
not require priming, and have relatively low affinity,
but is broadly reactive. The major effectors of innate
immunity are granulocytes,
monocytes/macrophages, natural killer cells and
mast cells.
2. Adaptive, or learned, immunity-It is antigen
specific, depends upon antigen exposure and have
very high affinity. The major effectors of adaptive
immunity are B and T lymphocytes. B lymphocytes
make antibodies; T lymphocytes function as helper,
cytolytic cells.
 Immunomodulators are the agents that modulates
the immune system by suppress or stimulate the
immune response.So, these are also divided into two
parts that are-
1.Immunosuppressants &
2.Immunostimulants
1.IMMUNOSUPPRESSANTS-
Immunosuppressive drugs are used to
dampen the immune response in organ
transplantation and autoimmune disease.
(a)Specific T-cell inhibitors-Cyclosporine,Tacrolimus
(b)Cytotoxic drugs-Azathioprine, Cyclophosphamide,
Methotrexate, Chlorambucil, Mycophenolate
mofetil(MMF)
(c)Glucocorticoids-Prednisolone
(d)Antibodies-Muromonab CD3, Antithymocyte
globulin(ATG), Rho(D) immunoglobulin
2.IMMUNOSTIMULANT-
These drugs are used to stimulate the immune response
in case of immunodeficiency.
(a) Levamisole (ergamisole)
(b) Thalidomide (thalomid)
(c) Bacillus Calmette-Guerin (BCG)
(d) Interferons- gamma1b & beta1a
(e) Interleukin-2
Screening method
 Acute systemic anaphylaxis in rats
 Anti-anaphylactic activity (schultz-dale reaction)
 Passive cutaneous anaphylaxis
 Arthus type immediate hypersensitivity
 Delayed type hypersensitivity
 Reversed passive arthus reaction
 Adjuvant arthritis in rats
Acute systemic anaphylaxis in rats
 Strain: 10-20 Female Sprague-Dawley rat(120g)
 Firstly immunized by i.m. injection of 10mg/kg
highly purified ovalbumin.
 Simultaneously 1ml of Bordetella pertusis
suspension injected intraperitoneally.
 After 11 days animals injected with i.v.
injection of 25mg/kg highly purified
ovalbumin
 18hr prior to challenge;
test – dexamethasone 1-10mg/kg s.c.
control-vehicle
 Evaluation-
after treatment compared treated and control
group for their shock symptoms and mortality
counted.
Statistical calculation is performed using the
chi-square test.
Modification-
 By Davis and Evans(1973)-This experiment have
also been performed in guinea pigs and in mice.
Anaphylactic bronchospasm can be measured in
isolated guinea pig lungs.
 By Ufkes and Ottenhof(1984)- studied on Brown-
Norway rats
Given a suspension of trinitrophenyl haptenized
ovalbumin together with AlPO4.
Bronchial and cardiovascular function were
studied after treatment with antiallergic agents and
antigen challenge.
 Elwood et al.(1992)- studied on Brown-Norway
rats.
They studied the effect of dexamethasone and
cyclosporin A on hyperresponsiveness and
inflammatory cell responses.
Anti-anaphylactic activity
(Schultz-Dale reaction)
 Animal-guinea pig of both sex
 Body wt.-300-350g
 Sensitized with alum precipitated egg
albumin.
 Give injection of 0.125ml of egg
albumin in each foot pad and 0.5ml
subcutaneously.
 After 4 weeks animals are killed and the ileum
is dissected out.
 About 2-3cm long are mounted in an organ
bath containing Tyrode solution at 370
C.
 Contractility of the ileum strips is tested by
adding standardin one organ bath and test
compound in another organ bath.
Biochemical estimation-
 Carbon clearance test- for phagocytic response
Phagocytic index=K(sample)/K(control)
 Hemagglutinating antibody titer
Evalution-
The contractions are recorded by a polygraph.
Modification-
 This method modified by testing histamine
release in the lung after challenging with egg
albumin.
 Koppel et al.(1981) developed a method to
induce contraction of mouse trachea by
antigen.
 Omote et al.(1994) modified method by using
sensitized guinea pigs.
Passive cutaneous anaphylaxis
 Animal-male rats
 Body wt.-100g
Principle-
 Formation of antigen-antibody complex induces the
release of mediator from mast cells.This results
increase in permeability of the vessel walls and
leakage of plasma.
Procedure-
 Antiserum are injected intradermally in to the
shaved dorsal skin of rats.
 After 24hr each animal is challenged with the
intravenous administration of 0.1ml of 2.5% Evans
blue dye containing 25mg/ml of egg albumin.
 Test compound is also administer along with the
antigen.
 After 30 min.,animals are sacrificed.
 Amount of Evans blue dye that leaked at the site of
reaction is extracted and determined
colorimetrically at 620milimicron wavelength.
Evaluation-
 Amount of Evans blue that extracted from passive
cutaneous anaphylactic reaction of control group is
compared with the treated group.
Modification-
 Goose and Blair(1969)- used Bordetella pertusis as
antigen in passive cutaneous anaphylaxis
experiments in the rat.
 Patterson et al.(1971)- tested passive cutaneous
reactivity to antihuman IgE in rhesus monkey.
Arthus type immediate hypersensitivity
 Animal-rats of both sex
 Strain-Wistar or Sprague-Dawley
 Body wt.-220-280g
Principle-
 Antigen-antibody induced reaction leading to an
inflammatory factors that characterised by
edeme,hamorrhage and vasculitis.
Procedure-
 Seven days prior to experiment rats are sensitized
by i.m. administration of 0.5ml of the ovalalbumin
suspension.
 1st
group(treated group)- 1hr prior test compound are
administered and challenged with 0.1ml of
ovalalbumin in left hind paw
 2nd
group(positive control)-sensitized animals treated
with solvent alone.
 3rd
group(negative control)-nonsensitized animals
treated with solvent.
Evalution-
 The change in footpad thickness is expressed as
percent change from the vehicle control group.
Thickness can be measured by calipers.
Modification-
 Omote et al.(1994)-sheep red blood cell suspension
used for immunization.
Delayed type hypersensitivity
Principle-
 Delayed type hypersensitivity is a reaction of cell
mediated immunity and becomes visible after 16-
24hr.
Procedure-
 7days prior,rats are sensitised by i.m. administration
of 0.5ml ovalbumin.
 After 7 days again 0.1ml of 0.04% of ovalbumin
injected in the left hind paw.
 Footpad thickness is measured immediately and
24hr after of administration.
Modification-
 Mizukoshi et al.(1994)-They use sheep red blood
cells for immunization.
References-
 Vogel.H.G. , second edition, Analgesics, page
no:797-801.
 Bigonia P. & Rana A.C. “Immunomodulatory
activity of EUPHORBIA NERIIFOLIA leaf
alcoholic extract on rats” Indian drugs, feb.2008
Screening methods of  immunomodulatory drugs

Contenu connexe

Tendances

Immunoassay of digoxin
Immunoassay of digoxinImmunoassay of digoxin
Immunoassay of digoxinAfreen Hashmi
 
Multiple sclerosis screening methods
Multiple sclerosis screening methodsMultiple sclerosis screening methods
Multiple sclerosis screening methodsmohamed abusalih
 
Assignment on Preclinical Screening of Immunomodulators
Assignment on Preclinical Screening of ImmunomodulatorsAssignment on Preclinical Screening of Immunomodulators
Assignment on Preclinical Screening of ImmunomodulatorsDeepak Kumar
 
Screening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugsScreening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugsHimikaRathi
 
Limitations of animal models part 1
Limitations of animal models part 1  Limitations of animal models part 1
Limitations of animal models part 1 Manohar Kuppala
 
Screening model of antidiarrheal activity Presented by ABDUL HAMEED
Screening model of antidiarrheal activity Presented by ABDUL HAMEEDScreening model of antidiarrheal activity Presented by ABDUL HAMEED
Screening model of antidiarrheal activity Presented by ABDUL HAMEEDAbdul Hameed
 
Screening of anti anginal and anti-allergic drugs -autosaved-
Screening of anti anginal and anti-allergic drugs -autosaved-Screening of anti anginal and anti-allergic drugs -autosaved-
Screening of anti anginal and anti-allergic drugs -autosaved-Gurubarath1
 
Anti-diarrhoeal screening models and methods
Anti-diarrhoeal screening models and methodsAnti-diarrhoeal screening models and methods
Anti-diarrhoeal screening models and methodsPervej Alom
 
Screening method of nootropics vikas malik
Screening method of nootropics vikas malikScreening method of nootropics vikas malik
Screening method of nootropics vikas malikVikasMalik68
 
Anti epileptic screening model
Anti epileptic screening modelAnti epileptic screening model
Anti epileptic screening modelKhushbooThakur15
 
Preclinical screening methods of cns stimulants
Preclinical screening methods of cns stimulantsPreclinical screening methods of cns stimulants
Preclinical screening methods of cns stimulantsRashmi116
 
Immunoassay of insulin (neha)
Immunoassay of insulin (neha)Immunoassay of insulin (neha)
Immunoassay of insulin (neha)ANANYAPANDEY71
 
Screening model for asthma COPD
Screening model for asthma COPDScreening model for asthma COPD
Screening model for asthma COPDJaineel Dharod
 
Screening Models of Antidepressants Drugs
Screening Models of Antidepressants DrugsScreening Models of Antidepressants Drugs
Screening Models of Antidepressants DrugsKomalSingh301
 
Assignment on Limitation of animal experimentation
Assignment on Limitation of animal experimentationAssignment on Limitation of animal experimentation
Assignment on Limitation of animal experimentationDeepak Kumar
 
Screening methods for anti angina
Screening methods for anti anginaScreening methods for anti angina
Screening methods for anti anginaDiana Lou
 
EXTRAPOLATION OF IN VITRO DATA TO PRECLINICAL TO HUMANS
EXTRAPOLATION OF IN VITRO DATA TO PRECLINICAL TO HUMANS EXTRAPOLATION OF IN VITRO DATA TO PRECLINICAL TO HUMANS
EXTRAPOLATION OF IN VITRO DATA TO PRECLINICAL TO HUMANS KARNATAKA COLLEGE OF PHARMACY
 

Tendances (20)

Immunoassay of digoxin
Immunoassay of digoxinImmunoassay of digoxin
Immunoassay of digoxin
 
opioid autocoids
opioid autocoidsopioid autocoids
opioid autocoids
 
Multiple sclerosis screening methods
Multiple sclerosis screening methodsMultiple sclerosis screening methods
Multiple sclerosis screening methods
 
Assignment on Preclinical Screening of Immunomodulators
Assignment on Preclinical Screening of ImmunomodulatorsAssignment on Preclinical Screening of Immunomodulators
Assignment on Preclinical Screening of Immunomodulators
 
Screening Models of Anti-Atherosclerosis
Screening Models of Anti-AtherosclerosisScreening Models of Anti-Atherosclerosis
Screening Models of Anti-Atherosclerosis
 
Screening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugsScreening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugs
 
Limitations of animal models part 1
Limitations of animal models part 1  Limitations of animal models part 1
Limitations of animal models part 1
 
Screening model of antidiarrheal activity Presented by ABDUL HAMEED
Screening model of antidiarrheal activity Presented by ABDUL HAMEEDScreening model of antidiarrheal activity Presented by ABDUL HAMEED
Screening model of antidiarrheal activity Presented by ABDUL HAMEED
 
Screening antianginal (1)
Screening antianginal (1)Screening antianginal (1)
Screening antianginal (1)
 
Screening of anti anginal and anti-allergic drugs -autosaved-
Screening of anti anginal and anti-allergic drugs -autosaved-Screening of anti anginal and anti-allergic drugs -autosaved-
Screening of anti anginal and anti-allergic drugs -autosaved-
 
Anti-diarrhoeal screening models and methods
Anti-diarrhoeal screening models and methodsAnti-diarrhoeal screening models and methods
Anti-diarrhoeal screening models and methods
 
Screening method of nootropics vikas malik
Screening method of nootropics vikas malikScreening method of nootropics vikas malik
Screening method of nootropics vikas malik
 
Anti epileptic screening model
Anti epileptic screening modelAnti epileptic screening model
Anti epileptic screening model
 
Preclinical screening methods of cns stimulants
Preclinical screening methods of cns stimulantsPreclinical screening methods of cns stimulants
Preclinical screening methods of cns stimulants
 
Immunoassay of insulin (neha)
Immunoassay of insulin (neha)Immunoassay of insulin (neha)
Immunoassay of insulin (neha)
 
Screening model for asthma COPD
Screening model for asthma COPDScreening model for asthma COPD
Screening model for asthma COPD
 
Screening Models of Antidepressants Drugs
Screening Models of Antidepressants DrugsScreening Models of Antidepressants Drugs
Screening Models of Antidepressants Drugs
 
Assignment on Limitation of animal experimentation
Assignment on Limitation of animal experimentationAssignment on Limitation of animal experimentation
Assignment on Limitation of animal experimentation
 
Screening methods for anti angina
Screening methods for anti anginaScreening methods for anti angina
Screening methods for anti angina
 
EXTRAPOLATION OF IN VITRO DATA TO PRECLINICAL TO HUMANS
EXTRAPOLATION OF IN VITRO DATA TO PRECLINICAL TO HUMANS EXTRAPOLATION OF IN VITRO DATA TO PRECLINICAL TO HUMANS
EXTRAPOLATION OF IN VITRO DATA TO PRECLINICAL TO HUMANS
 

En vedette

Screening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive AgentsScreening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive AgentsDr. Advaitha MV
 
In- vitro and in-vivo screening of Hypoglycemics.
In- vitro and in-vivo screening of Hypoglycemics.In- vitro and in-vivo screening of Hypoglycemics.
In- vitro and in-vivo screening of Hypoglycemics.Student
 
Experimental evaluation of anti-diabetics
Experimental evaluation of anti-diabeticsExperimental evaluation of anti-diabetics
Experimental evaluation of anti-diabeticsKirtan Bhatt
 
Anticancer drug screening
Anticancer drug screeningAnticancer drug screening
Anticancer drug screeningshishirkawde
 
Screening of antihypertensive agents
Screening of antihypertensive agentsScreening of antihypertensive agents
Screening of antihypertensive agentsKanthlal SK
 
Preclinical and clinical screening of anticancer drugs
Preclinical and clinical screening of anticancer drugsPreclinical and clinical screening of anticancer drugs
Preclinical and clinical screening of anticancer drugsBanhisikha Adhikari
 

En vedette (6)

Screening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive AgentsScreening Methods of Antihypertensive Agents
Screening Methods of Antihypertensive Agents
 
In- vitro and in-vivo screening of Hypoglycemics.
In- vitro and in-vivo screening of Hypoglycemics.In- vitro and in-vivo screening of Hypoglycemics.
In- vitro and in-vivo screening of Hypoglycemics.
 
Experimental evaluation of anti-diabetics
Experimental evaluation of anti-diabeticsExperimental evaluation of anti-diabetics
Experimental evaluation of anti-diabetics
 
Anticancer drug screening
Anticancer drug screeningAnticancer drug screening
Anticancer drug screening
 
Screening of antihypertensive agents
Screening of antihypertensive agentsScreening of antihypertensive agents
Screening of antihypertensive agents
 
Preclinical and clinical screening of anticancer drugs
Preclinical and clinical screening of anticancer drugsPreclinical and clinical screening of anticancer drugs
Preclinical and clinical screening of anticancer drugs
 

Similaire à Screening methods of immunomodulatory drugs

Screening methods of immunomodulators by shivam diwaker
Screening methods of immunomodulators by shivam diwakerScreening methods of immunomodulators by shivam diwaker
Screening methods of immunomodulators by shivam diwakerShivam Diwaker
 
Screening models for immunomodulators
Screening models for immunomodulatorsScreening models for immunomodulators
Screening models for immunomodulatorsurmisthasarkar
 
Screening methods of immunomodulators
Screening methods of immunomodulatorsScreening methods of immunomodulators
Screening methods of immunomodulatorsAanchal46
 
Screening models for immunomodulatory agents
Screening models for immunomodulatory agentsScreening models for immunomodulatory agents
Screening models for immunomodulatory agentsChandragiri Siva Sai
 
SCREENING OF immuno.pptx
SCREENING OF immuno.pptxSCREENING OF immuno.pptx
SCREENING OF immuno.pptxSourinDe2
 
IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)iosrphr_editor
 
Immunomodulators screening methods
Immunomodulators screening methodsImmunomodulators screening methods
Immunomodulators screening methodsVIGNESHROSS
 
Immunodulators Screening methods
Immunodulators Screening methodsImmunodulators Screening methods
Immunodulators Screening methodsANANYAPANDEY71
 
Anxiolytic poonam ppt.pptx
Anxiolytic poonam ppt.pptxAnxiolytic poonam ppt.pptx
Anxiolytic poonam ppt.pptxPoonamJoshi51
 
Screnning of immunomodolator
Screnning of immunomodolatorScrenning of immunomodolator
Screnning of immunomodolatorssuser3f154a
 
Src jbbr-21-125 Dr. ihsan edan abdulkareem alsaimary PROFESSOR IN MEDICAL M...
Src jbbr-21-125  Dr. ihsan edan abdulkareem alsaimary  PROFESSOR IN MEDICAL M...Src jbbr-21-125  Dr. ihsan edan abdulkareem alsaimary  PROFESSOR IN MEDICAL M...
Src jbbr-21-125 Dr. ihsan edan abdulkareem alsaimary PROFESSOR IN MEDICAL M...dr.Ihsan alsaimary
 
Pharmacological screening of analgesic activity
Pharmacological screening of analgesic activityPharmacological screening of analgesic activity
Pharmacological screening of analgesic activityBiswash Sapkota
 
Eva. bio. & toxicity 112070804015
Eva. bio. & toxicity  112070804015Eva. bio. & toxicity  112070804015
Eva. bio. & toxicity 112070804015Patel Parth
 
Eva. bio. & toxicity 112070804015
Eva. bio. & toxicity  112070804015Eva. bio. & toxicity  112070804015
Eva. bio. & toxicity 112070804015Patel Parth
 
Pre clinical screening of anti epileptic drugs
Pre clinical screening of anti epileptic drugsPre clinical screening of anti epileptic drugs
Pre clinical screening of anti epileptic drugsHinnaHamid1
 

Similaire à Screening methods of immunomodulatory drugs (20)

Screening methods of immunomodulators by shivam diwaker
Screening methods of immunomodulators by shivam diwakerScreening methods of immunomodulators by shivam diwaker
Screening methods of immunomodulators by shivam diwaker
 
Screening models for immunomodulators
Screening models for immunomodulatorsScreening models for immunomodulators
Screening models for immunomodulators
 
Screening methods of immunomodulators
Screening methods of immunomodulatorsScreening methods of immunomodulators
Screening methods of immunomodulators
 
ELISA.pptx
ELISA.pptxELISA.pptx
ELISA.pptx
 
Screening models for immunomodulatory agents
Screening models for immunomodulatory agentsScreening models for immunomodulatory agents
Screening models for immunomodulatory agents
 
SCREENING OF immuno.pptx
SCREENING OF immuno.pptxSCREENING OF immuno.pptx
SCREENING OF immuno.pptx
 
IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)IOSR Journal of Pharmacy (IOSRPHR)
IOSR Journal of Pharmacy (IOSRPHR)
 
Immunomodulators screening methods
Immunomodulators screening methodsImmunomodulators screening methods
Immunomodulators screening methods
 
ANTIALLERGICS’.pptx
ANTIALLERGICS’.pptxANTIALLERGICS’.pptx
ANTIALLERGICS’.pptx
 
Immunodulators Screening methods
Immunodulators Screening methodsImmunodulators Screening methods
Immunodulators Screening methods
 
Anxiolytic poonam ppt.pptx
Anxiolytic poonam ppt.pptxAnxiolytic poonam ppt.pptx
Anxiolytic poonam ppt.pptx
 
NYCSEF
NYCSEFNYCSEF
NYCSEF
 
Screnning of immunomodolator
Screnning of immunomodolatorScrenning of immunomodolator
Screnning of immunomodolator
 
Src jbbr-21-125 Dr. ihsan edan abdulkareem alsaimary PROFESSOR IN MEDICAL M...
Src jbbr-21-125  Dr. ihsan edan abdulkareem alsaimary  PROFESSOR IN MEDICAL M...Src jbbr-21-125  Dr. ihsan edan abdulkareem alsaimary  PROFESSOR IN MEDICAL M...
Src jbbr-21-125 Dr. ihsan edan abdulkareem alsaimary PROFESSOR IN MEDICAL M...
 
Pharmacological screening of analgesic activity
Pharmacological screening of analgesic activityPharmacological screening of analgesic activity
Pharmacological screening of analgesic activity
 
Eva. bio. & toxicity 112070804015
Eva. bio. & toxicity  112070804015Eva. bio. & toxicity  112070804015
Eva. bio. & toxicity 112070804015
 
Eva. bio. & toxicity 112070804015
Eva. bio. & toxicity  112070804015Eva. bio. & toxicity  112070804015
Eva. bio. & toxicity 112070804015
 
Pre clinical screening of anti epileptic drugs
Pre clinical screening of anti epileptic drugsPre clinical screening of anti epileptic drugs
Pre clinical screening of anti epileptic drugs
 
immunomodulatry potential.pptx
immunomodulatry potential.pptximmunomodulatry potential.pptx
immunomodulatry potential.pptx
 
ELISA Notes
ELISA NotesELISA Notes
ELISA Notes
 

Screening methods of immunomodulatory drugs

  • 1. PRESENTED BYPRESENTED BY:-:- Prafulla C TiwariPrafulla C Tiwari M.Pharm (2M.Pharm (2ndnd sem)sem) PharmacologyPharmacology UNDER THE GUIDANCE OF:- MR. RUPESH GAUTAM (Lecturer) Department Of Pharmacology
  • 2.  The immune system evolved to discriminate self from nonself.  Multicellular organism shows immune response by destroying infectious invaders (microbes) while leaving normal cells intact.  Immunity system shows two types of responses that are- 1.Innate immunity 2.Adaptive immunity
  • 3. 1.Innate, or natural immunity-It is primitive, does not require priming, and have relatively low affinity, but is broadly reactive. The major effectors of innate immunity are granulocytes, monocytes/macrophages, natural killer cells and mast cells. 2. Adaptive, or learned, immunity-It is antigen specific, depends upon antigen exposure and have very high affinity. The major effectors of adaptive immunity are B and T lymphocytes. B lymphocytes make antibodies; T lymphocytes function as helper, cytolytic cells.
  • 4.  Immunomodulators are the agents that modulates the immune system by suppress or stimulate the immune response.So, these are also divided into two parts that are- 1.Immunosuppressants & 2.Immunostimulants
  • 5. 1.IMMUNOSUPPRESSANTS- Immunosuppressive drugs are used to dampen the immune response in organ transplantation and autoimmune disease. (a)Specific T-cell inhibitors-Cyclosporine,Tacrolimus (b)Cytotoxic drugs-Azathioprine, Cyclophosphamide, Methotrexate, Chlorambucil, Mycophenolate mofetil(MMF) (c)Glucocorticoids-Prednisolone (d)Antibodies-Muromonab CD3, Antithymocyte globulin(ATG), Rho(D) immunoglobulin
  • 6. 2.IMMUNOSTIMULANT- These drugs are used to stimulate the immune response in case of immunodeficiency. (a) Levamisole (ergamisole) (b) Thalidomide (thalomid) (c) Bacillus Calmette-Guerin (BCG) (d) Interferons- gamma1b & beta1a (e) Interleukin-2
  • 7. Screening method  Acute systemic anaphylaxis in rats  Anti-anaphylactic activity (schultz-dale reaction)  Passive cutaneous anaphylaxis  Arthus type immediate hypersensitivity  Delayed type hypersensitivity  Reversed passive arthus reaction  Adjuvant arthritis in rats
  • 8. Acute systemic anaphylaxis in rats  Strain: 10-20 Female Sprague-Dawley rat(120g)  Firstly immunized by i.m. injection of 10mg/kg highly purified ovalbumin.  Simultaneously 1ml of Bordetella pertusis suspension injected intraperitoneally.  After 11 days animals injected with i.v. injection of 25mg/kg highly purified ovalbumin  18hr prior to challenge; test – dexamethasone 1-10mg/kg s.c. control-vehicle
  • 9.  Evaluation- after treatment compared treated and control group for their shock symptoms and mortality counted. Statistical calculation is performed using the chi-square test.
  • 10. Modification-  By Davis and Evans(1973)-This experiment have also been performed in guinea pigs and in mice. Anaphylactic bronchospasm can be measured in isolated guinea pig lungs.  By Ufkes and Ottenhof(1984)- studied on Brown- Norway rats Given a suspension of trinitrophenyl haptenized ovalbumin together with AlPO4. Bronchial and cardiovascular function were studied after treatment with antiallergic agents and antigen challenge.
  • 11.  Elwood et al.(1992)- studied on Brown-Norway rats. They studied the effect of dexamethasone and cyclosporin A on hyperresponsiveness and inflammatory cell responses.
  • 12. Anti-anaphylactic activity (Schultz-Dale reaction)  Animal-guinea pig of both sex  Body wt.-300-350g  Sensitized with alum precipitated egg albumin.  Give injection of 0.125ml of egg albumin in each foot pad and 0.5ml subcutaneously.
  • 13.  After 4 weeks animals are killed and the ileum is dissected out.  About 2-3cm long are mounted in an organ bath containing Tyrode solution at 370 C.  Contractility of the ileum strips is tested by adding standardin one organ bath and test compound in another organ bath.
  • 14. Biochemical estimation-  Carbon clearance test- for phagocytic response Phagocytic index=K(sample)/K(control)  Hemagglutinating antibody titer
  • 15. Evalution- The contractions are recorded by a polygraph. Modification-  This method modified by testing histamine release in the lung after challenging with egg albumin.  Koppel et al.(1981) developed a method to induce contraction of mouse trachea by antigen.  Omote et al.(1994) modified method by using sensitized guinea pigs.
  • 16. Passive cutaneous anaphylaxis  Animal-male rats  Body wt.-100g Principle-  Formation of antigen-antibody complex induces the release of mediator from mast cells.This results increase in permeability of the vessel walls and leakage of plasma.
  • 17. Procedure-  Antiserum are injected intradermally in to the shaved dorsal skin of rats.  After 24hr each animal is challenged with the intravenous administration of 0.1ml of 2.5% Evans blue dye containing 25mg/ml of egg albumin.  Test compound is also administer along with the antigen.  After 30 min.,animals are sacrificed.  Amount of Evans blue dye that leaked at the site of reaction is extracted and determined colorimetrically at 620milimicron wavelength.
  • 18. Evaluation-  Amount of Evans blue that extracted from passive cutaneous anaphylactic reaction of control group is compared with the treated group. Modification-  Goose and Blair(1969)- used Bordetella pertusis as antigen in passive cutaneous anaphylaxis experiments in the rat.  Patterson et al.(1971)- tested passive cutaneous reactivity to antihuman IgE in rhesus monkey.
  • 19. Arthus type immediate hypersensitivity  Animal-rats of both sex  Strain-Wistar or Sprague-Dawley  Body wt.-220-280g Principle-  Antigen-antibody induced reaction leading to an inflammatory factors that characterised by edeme,hamorrhage and vasculitis.
  • 20. Procedure-  Seven days prior to experiment rats are sensitized by i.m. administration of 0.5ml of the ovalalbumin suspension.  1st group(treated group)- 1hr prior test compound are administered and challenged with 0.1ml of ovalalbumin in left hind paw  2nd group(positive control)-sensitized animals treated with solvent alone.  3rd group(negative control)-nonsensitized animals treated with solvent.
  • 21. Evalution-  The change in footpad thickness is expressed as percent change from the vehicle control group. Thickness can be measured by calipers. Modification-  Omote et al.(1994)-sheep red blood cell suspension used for immunization.
  • 22. Delayed type hypersensitivity Principle-  Delayed type hypersensitivity is a reaction of cell mediated immunity and becomes visible after 16- 24hr. Procedure-  7days prior,rats are sensitised by i.m. administration of 0.5ml ovalbumin.  After 7 days again 0.1ml of 0.04% of ovalbumin injected in the left hind paw.
  • 23.  Footpad thickness is measured immediately and 24hr after of administration. Modification-  Mizukoshi et al.(1994)-They use sheep red blood cells for immunization.
  • 24. References-  Vogel.H.G. , second edition, Analgesics, page no:797-801.  Bigonia P. & Rana A.C. “Immunomodulatory activity of EUPHORBIA NERIIFOLIA leaf alcoholic extract on rats” Indian drugs, feb.2008